title: [T2 laryngeal cancer study in our department].
abstract: Laryngeal cancer is the most common malignant tumor in the head and neck region.Because early detection and treatment are possible, outcomes are relatively good.Many studies have reported on the treatment of laryngeal cancer.Different hospitals have used generally similar treatment regimens.However, factors such as laryngeal preservation and the treatment of choice for patients with T2 laryngeal cancer still differ among hospitals.Survival rates can be increased depending on treatment, sometimes at the cost of losing voice functions that could have been preserved.In our department, we have emphasized curative treatment and the preservation of organs and functions.We have mainly used chemoradiotherapy concurrently with S-1 and nedaplatin for the treatment of T2 laryngeal cancer.We studied 27 patients(23 men and 4 women)with T2 laryngeal cancer, who received first-line therapy in our department from April 2005 through March 2010. Their mean age was 64.1 years(range, 42 to 80).The mean follow-up period was 30.6 months(range, 2 to 60 months).The tumor-nodemetastasis classification was T2N0M0 in 24 patients, T2N1M0 in 1, and T2N2bM0 in 2.In our department, the disease-specific survival rate was 96.3%. The complete response rate was 88.9%, and the laryngeal preservation rate was 92.6%.
authors.affiliation: Dept. of Otorhinolaryngology, Showa University, Japan.
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Ikenoya
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Shimane
authors.forename: Sei
authors.initials: S
authors.lastname: Kobayashi
authors.forename: Rio
authors.initials: R
authors.lastname: Akiyama
authors.forename: Aya
authors.initials: A
authors.lastname: Uzuki
authors.forename: Akane
authors.initials: A
authors.lastname: Sugimoto
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hayashi
authors.forename: Kenichiro
authors.initials: K
authors.lastname: Ikeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Gomibuchi
authors.forename: Takeyuki
authors.initials: T
authors.lastname: Sanbe
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D059248:Chemoradiotherapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007822:Laryngeal Neoplasms / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C053989:nedaplatin